Profund Advisors LLC Buys Shares of 21,220 Celcuity, Inc. $CELC

Profund Advisors LLC bought a new stake in Celcuity, Inc. (NASDAQ:CELC) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 21,220 shares of the company’s stock, valued at approximately $2,116,000.

Several other hedge funds have also recently bought and sold shares of CELC. Apis Capital Advisors LLC bought a new position in Celcuity in the 3rd quarter valued at about $38,334,000. UBS Group AG increased its holdings in Celcuity by 910.1% in the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after buying an additional 769,891 shares during the period. Deerfield Management Company L.P. bought a new position in Celcuity in the 3rd quarter valued at about $36,236,000. Alliancebernstein L.P. increased its holdings in Celcuity by 2,208.6% in the 3rd quarter. Alliancebernstein L.P. now owns 652,649 shares of the company’s stock valued at $32,241,000 after buying an additional 624,379 shares during the period. Finally, Soleus Capital Management L.P. boosted its stake in shares of Celcuity by 17.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after purchasing an additional 437,696 shares in the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Down 0.8%

NASDAQ:CELC opened at $131.09 on Wednesday. The firm’s 50 day simple moving average is $119.52 and its 200 day simple moving average is $107.75. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. Celcuity, Inc. has a one year low of $10.26 and a one year high of $151.02. The company has a market cap of $6.39 billion, a PE ratio of -33.61 and a beta of 0.09.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. On average, research analysts anticipate that Celcuity, Inc. will post -3.87 earnings per share for the current year.

Insider Activity at Celcuity

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. The trade was a 27.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Craig Hallum restated a “buy” rating and issued a $189.00 price target on shares of Celcuity in a research note on Monday, May 4th. HC Wainwright raised their price target on shares of Celcuity from $165.00 to $185.00 and gave the company a “buy” rating in a research note on Monday. Wells Fargo & Company raised their price target on shares of Celcuity from $150.00 to $183.00 and gave the company an “overweight” rating in a research note on Friday. Citigroup restated an “outperform” rating on shares of Celcuity in a research note on Monday, May 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $157.00 price target on shares of Celcuity in a research note on Friday, May 15th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $149.30.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.